Innate Pharma SA (IPHYF)
2.20
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Innate Pharma Enterprise Value: 118.83M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 118.83M |
| May 30, 2024 | 118.83M |
| May 29, 2024 | 118.83M |
| May 28, 2024 | 118.83M |
| May 24, 2024 | 118.83M |
| May 23, 2024 | 118.83M |
| May 22, 2024 | 118.83M |
| May 21, 2024 | 118.83M |
| May 20, 2024 | 118.83M |
| May 17, 2024 | 118.83M |
| May 16, 2024 | 118.83M |
| May 15, 2024 | 118.83M |
| May 14, 2024 | 118.83M |
| May 13, 2024 | 118.83M |
| May 10, 2024 | 118.83M |
| May 09, 2024 | 118.83M |
| May 08, 2024 | 118.83M |
| May 07, 2024 | 118.83M |
| May 06, 2024 | 113.17M |
| May 03, 2024 | 113.17M |
| May 02, 2024 | 155.21M |
| May 01, 2024 | 155.21M |
| April 30, 2024 | 155.21M |
| April 29, 2024 | 155.21M |
| April 26, 2024 | 155.21M |
| Date | Value |
|---|---|
| April 25, 2024 | 155.21M |
| April 24, 2024 | 155.21M |
| April 23, 2024 | 155.21M |
| April 22, 2024 | 155.21M |
| April 19, 2024 | 155.21M |
| April 18, 2024 | 155.21M |
| April 17, 2024 | 155.21M |
| April 16, 2024 | 155.21M |
| April 15, 2024 | 155.21M |
| April 12, 2024 | 155.21M |
| April 11, 2024 | 155.21M |
| April 10, 2024 | 155.21M |
| April 09, 2024 | 155.21M |
| April 08, 2024 | 155.21M |
| April 05, 2024 | 155.21M |
| April 04, 2024 | 155.21M |
| April 03, 2024 | 155.21M |
| April 02, 2024 | 155.21M |
| April 01, 2024 | 149.55M |
| March 28, 2024 | 149.55M |
| March 27, 2024 | 130.18M |
| March 26, 2024 | 134.59M |
| March 25, 2024 | 134.59M |
| March 22, 2024 | 134.59M |
| March 21, 2024 | 134.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
70.21M
Minimum
Mar 16 2020
501.94M
Maximum
Sep 17 2021
205.69M
Average
188.27M
Median
Jul 28 2023
Enterprise Value Benchmarks
| DBV Technologies SA | 4.478M |
| Cellectis SA | 167.93M |
| PHAXIAM Therapeutics SA (DELISTED) | -8.542M |
| Genfit SA | 242.87M |
Enterprise Value Related Metrics
| Earnings Yield | -4.39% |
| Normalized Earnings Yield | -4.393 |